Embecta Corp (FRA:JX7)
€ 11.6 -0.2 (-1.69%) Market Cap: 658.85 Mil Enterprise Value: 1.89 Bil PE Ratio: 10.28 PB Ratio: 0 GF Score: 26/100

Embecta Corp at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 10:15PM GMT
Release Date Price: €16.6 (-3.49%)
Caroline Borowski J.P. Morgan;Analyst

Hi, all. My name is Caroline Borowski, and I'm part of the healthcare investment banking group here at J.P. Morgan. And it's my pleasure to introduce Dev Kurdikar, the CEO; and Jake Elguicze, the CFO of Embecta.

Devdatt Kurdikar
Embecta Corp - President, Chief Executive Officer, Director

Good afternoon, everybody, and thank you, Caroline, for having us. It's a pleasure to be here with you today. With me, as Karen mentioned, we have Jake Elguicze, our Chief Financial Officer. Pravesh, our Head of IR, is in the audience as well. What I thought we would do over the next 20 minutes or so is give you a little bit of an update on where we are at our company, talk a little bit about our path forward. And I know we'll have some Q&A towards the end as well. But for those of you -- and this is our forward-looking statement language. For those of you that don't know us, because we are a new company, let me just take a moment to tell you who we are.

Embecta is a company devoted to developing and providing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot